estramustine


Also found in: Dictionary, Wikipedia.

estramustine

 [es″trah-mus´tēn]
an antineoplastic agent containing estradiol joined to mechlorethamine; administered orally for palliative treatment of metastatic or progressive carcinoma of the prostate; used as estramustine phosphate sodium.

estramustine

/es·tra·mus·tine/ (-mus´tēn) an antineoplastic containing estradiol joined to mechlorethamine, used for palliative treatment of metastatic or progressive carcinoma of the prostate; used as e. phosphate sodium.

estramustine

(ĕs′trə-mŭs′tēn′)
n.
A drug, C23H31Cl2NO3, that combines the actions of estrogen and nitrogen mustard in the treatment of prostate cancer.

estramustine

[es′trämus′tēn]
an antineoplastic agent containing estradiol joined to mechlorethamine, administered orally for palliative treatment of metastatic or progressive carcinoma of the prostate. It is used as estramustine phosphate sodium.

estramustine

Oncology A combination of estradiol and nitrogen mustard used in the palliative therapy of prostate CA. See Prostate CA.

estramustine

An alkylating anti-cancer drug. A brand name is Estracyt.
References in periodicals archive ?
4C only during treatment with Taxane/ estramustine and was not detected before or after treatment.
A multifold increase of [Beta]III transcript expression has been shown in nonneuronal tumors, such as non-small cell lung cancer, and in ovarian and prostate cancer cell lines, particularly in those exhibiting resistance to a class of antimicrotubule (microtubule-polymerizing) drugs, such as estramustine and paclitaxel (Taxol).
Estramustine disodium phosphate Sales volume and market share
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Single-agent estramustine and single-agent Taxotere see equal use in the first-line treatment of HRPC when the seven-market average is examined despite a lack of robust supporting clinical data 145
5] the authors used docetaxel, carboplatin and estramustine as second-line chemotherapy, after previously observed progression on docetaxel chemotherapy, with excellent clinical and biochemical response.
Moreover, all of the patients in the study had failed treatment with docetaxel and 10 patients (36%) had failed treatment with an additional cytotoxic agent (mitoxantrone, estramustine, vinorelbine, cyclophosphamide).
Moreover, all of the patients in the study had failed treatment with docetaxel and 10 patients (33%) had failed treatment with an additional cytotoxic agent (mitoxantrone, estramustine, vinorelbine, cyclophosphamide).
Petrylak and colleagues reported on 666 eligible patients randomized to docetaxel and estramustine (EMP) or mitoxantrone-prednisone.
The chemotherapies administered to patients in Groups B and C were very similar and consisted of mitoxantrone plus prednisone or estramustine phosphate.
Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives.